Depression and Inflammatory Biomarkers in Women with Type 2 Diabetes

This cross-sectional pilot study contains data from 38 women with type 2 diabetes, 82% of whom also have HIV, collected from 2022-2023. It includes serum levels of 10 inflammatory biomarkers (hsCRP, INF-γ, IL-1β, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α) and scores from multiple depression and symptom measures (CES-D, PROMIS-Depression, PROMIS-Anxiety, PROMIS-Fatigue, PROMIS-Sleep).

Use Cases

• Analyze correlations between IL-4 levels and PROMIS-Depression or PROMIS-Anxiety scores in a cohort of women with T2D.
• Explore associations between hsCRP and IL-6 levels and different depression measures like CES-D and PROMIS-Depression.
• Investigate the relationship between PROMIS-Sleep scores and IL-8 biomarker levels.
• Examine demographic and clinical variables (age, BMI, HbA1c, HIV status) alongside inflammatory biomarker profiles.

Strengths

• Includes 10 distinct serum inflammatory biomarkers measured via Luminex assay.
• Uses multiple validated depression and symptom measures (CES-D and PROMIS scales).
• Provides detailed participant demographics: mean age 61.4, 71% Black, 32% Hispanic, mean BMI 34.7, mean HbA1c 6.5%.

Limitations

• Small sample size of 38 participants limits statistical power and generalizability.
• Cross-sectional design from a single site prevents causal or longitudinal analysis.
• Specific cohort characteristics (82% with HIV, all women with T2D) may not represent broader populations.

Provenance

Source

MACS/WIHS Combined Cohort Study (MWCCS) Bronx site.

Collection Method

Cross-sectional pilot study with serum biomarker measurement and survey administration.

Time Range

2022-2023

Freshness

Data collected from 2022-2023, with a platform last update in 2026.

Geography

Bronx, New York, United States.